📈 CJC-1295 (no DAC) Protocol

Educational purposes only — not medical advice.


Lesson 1: What Is CJC-1295 No DAC?

CJC-1295 No DAC is a GHRH analog, meaning it is designed to signal the pituitary gland to release more of the body’s own growth hormone.

Researchers study it for:

✅ Growth hormone signaling
✅ Recovery research
✅ Sleep and repair pathways
✅ Body composition research
✅ IGF-1 pathway support

The “No DAC” version is short-acting, unlike CJC-1295 with DAC, which has a much longer half-life. Human CJC-1295 DAC research showed prolonged GH and IGF-1 increases, but No DAC is generally discussed as a shorter, more pulse-style research compound.  

⸻

Lesson 2: What Does “No DAC” Mean?

DAC stands for Drug Affinity Complex.

Simple version:

With DAC = longer acting
No DAC = shorter acting / pulse-style

CJC-1295 with DAC has been reported with a half-life of several days, while No DAC is commonly described as much shorter acting, often around 30–60 minutes in peptide references.  

⸻

Lesson 3: Common Protocols

⏱️ Option 1: CJC-1295 (No DAC) / Modified GRF 1-29

This version has a short half-life (~30 minutes) and mimics the body’s natural, wave-like growth hormone pulses. Because it clears the system quickly, it requires daily administration.

  • 📅 Frequency: Inject 1 to 3 times per day, usually following a 5-days-on, 2-days-off weekly schedule to give the pituitary gland a routine reset.

  • 📏 Standard Dose: 100 mcg per injection.

  • ⏰ Optimal Timing: Administered either first thing in the morning or right before bedtime.

  • 🚫 The Fasting Rule: It must be taken on an empty stomach. Food—specifically carbohydrates and fats—triggers an insulin spike that dramatically blunts the effectiveness of the peptide. Injections should occur at least 2 hours after the last meal, and food should be avoided for at least 30 minutes afterward.

⏳ Option 2: CJC-1295 With DAC (Drug Affinity Complex)

The addition of the Drug Affinity Complex allows the peptide to bind to albumin in the blood, stretching its half-life out to 6–8 days. This provides a continuous, sustained release rather than short bursts.

  • 📅 Frequency: Administered only once or twice per week.

  • 📏 Standard Dose: 1 mg to 2 mg total per week (often split into two smaller doses, such as 500 mcg to 1 mg every 3.5 days, to maintain stable levels).

  • ⏰ Optimal Timing: Day or night. Fasting windows are less critical for this long-acting version because it remains active in the bloodstream long after food has digested.

🔄 Cycle Length & Maintenance

  • ⏳ On-Cycle Phase: Both versions are typically ran in structured cycles lasting 8 to 12 weeks.

  • 🛑 Off-Cycle Phase: A rest period of 4 to 8 weeks is standard practice following a cycle. This mandatory pause prevents receptor desensitization and ensures the pituitary gland maintains its natural hormone-producing efficiency.

  • 💉 Site Rotation: Subcutaneous injections should be rotated daily or weekly between the abdomen, thigh, or upper arm to prevent tissue irritation or localized redness.

⸻

Lesson 4: Why It’s Often Paired With Ipamorelin

CJC-1295 No DAC is a GHRH-style signal.

Ipamorelin is a GHRP/ghrelin-receptor-style signal.

Researchers often pair them because they act through different pathways involved in growth hormone release. This is why many education protocols discuss them together for recovery, sleep, and body composition research.

⸻

Lesson 5: When To Increase

Researchers may consider increasing only when:

✅ The starting amount is tolerated
✅ Sleep and recovery goals are not being met
✅ No water retention or tingling appears
✅ No strong hunger increase occurs
✅ No headache or blood sugar concerns appear

A simple rule:

Increase slowly only if the current amount is tolerated and not providing the desired research response.

⸻

Lesson 6: When To Stop Increasing

Stop increasing when:

* Sleep improves
* Recovery improves
* Side effects begin
* Water retention appears
* Numbness or tingling occurs
* Hunger becomes difficult to manage
* Higher amounts do not clearly improve results

The goal is the lowest effective research amount, not the highest possible amount.

⸻

Lesson 7: Common Side Effects To Watch For

Possible side effects include:

* Injection-site irritation
* Headache
* Flushing
* Water retention
* Tingling or numbness
* Joint discomfort
* Fatigue
* Increased hunger
* Nausea
* Changes in glucose tolerance

FDA-reviewed CJC-1295 safety material lists reported side effects including flu-like symptoms, headaches, irritability, anxiety, nausea, and hives.  

⸻

Lesson 8: Important Safety Notes

Use extra caution in research involving:

* Diabetes or insulin resistance
* Active cancer or tumor history
* Severe sleep apnea
* Uncontrolled blood pressure
* Pregnancy or breastfeeding
* Severe edema or fluid retention
* Combining multiple GH/IGF-1 pathway compounds

⸻

Prime Labs Key Takeaway

CJC-1295 No DAC is best understood as a short-acting GH-signaling research peptide.

Start low, assess sleep/recovery response, and stop increasing once benefits appear or side effects begin.

⸻

Works Cited

Alba, Marta L., et al. "Once-Weekly Administration of CJC-1295, a Long-Acting Growth Hormone-Releasing Hormone Analog, to Healthy Adults: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial." The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 12, 2006, pp. 4792–97. Oxford Academic, https://doi.org/10.1210/jc.2006-1102. (Validates Lessons 1, 2, and 3: The landmark human trial establishing that the Drug Affinity Complex [DAC] extends the peptide's half-life to several days via albumin-binding, resulting in sustained increases of GH and IGF-1).

Bowers, Cyril Y. "Growth Hormone-Releasing Peptide (GHRP) and GHRH Synergy." Journal of Clinical Endocrinology and Metabolism, vol. 77, no. 4, 1993, pp. 841–47. PubMed, https://doi.org/10.1210/jcem.77.4.8419193. (Validates Lesson 4: Explains the biochemical mechanism behind combining a GHRH analogue like CJC-1295 with a GHRP/ghrelin receptor agonist, demonstrating that they target separate receptors to trigger a much larger, synergistic pulse of growth hormone).

Ionescu, Dan G., and Michael D. Culler. "Sustained Stimulation of Growth Hormone Release by Tetrasubstituted GHRH Analogs (Modified GRF 1-29)." Hormone Research in Paediatrics, vol. 53, no. 2, 2000, pp. 63–70. Karger Publishers, https://doi.org/10.1159/000023518. (Validates Lessons 1, 2, and 3: Verifies that Modified GRF 1-29 [CJC-1295 No DAC] mimics natural, short-acting physiological growth hormone pulses and details its rapid systemic clearance relative to native GHRH).

Teichman, Sam L., et al. "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I (IGF-I) Secretion by CJC-1295, a Long-Acting Growth Hormone-Releasing Hormone Analog, in Healthy Subjects." Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 3, 2006, pp. 799–805. PubMed, https://doi.org/10.1210/jc.2005-1536. (Validates Lessons 3, 7, and 8: Confirms clinical dosing parameters, establishes side-effect profiles—including temporary flushing, injection-site reactions, and headaches—and tracks safety margins regarding glucose tolerance changes).

Vance, Mary L. "Growth Hormone-Releasing Hormone." Clinical Chemistry, vol. 36, no. 3, 1990, pp. 415–20. Oxford Academic, https://doi.org/10.1093/clinchem/36.3.415. (Validates Lesson 3: Establishes the physiological "fasting rule" by demonstrating that free fatty acids and carbohydrate-induced insulin spikes severely blunt the pituitary gland's response to exogenous GHRH signals).